122 related articles for article (PubMed ID: 23812262)
1. Deal watch: AbbVie invests in pioneering celiac disease therapy.
Crunkhorn S
Nat Rev Drug Discov; 2013 Jul; 12(7):497. PubMed ID: 23812262
[No Abstract] [Full Text] [Related]
2. Market watch: Upcoming market catalysts in Q2 2013.
Nguyen K
Nat Rev Drug Discov; 2013 Apr; 12(4):254. PubMed ID: 23535926
[No Abstract] [Full Text] [Related]
3. Deal watch: Merck invests in pioneering cytomegalovirus programme.
Crunkhorn S
Nat Rev Drug Discov; 2012 Dec; 11(12):896. PubMed ID: 23197025
[No Abstract] [Full Text] [Related]
4. The cost of bringing a radiopharmaceutical to the patient's bedside.
Nunn AD
J Nucl Med; 2007 Feb; 48(2):169. PubMed ID: 17268008
[No Abstract] [Full Text] [Related]
5. Financing gene therapy beyond phase II.
Michael A
Gene Ther; 1996 Dec; 3(12):1035-8. PubMed ID: 9072181
[TBL] [Abstract][Full Text] [Related]
6. Market watch: Upcoming market catalysts in Q3 2013.
Roybal D
Nat Rev Drug Discov; 2013 Jul; 12(7):496. PubMed ID: 23812261
[No Abstract] [Full Text] [Related]
7. Market watch: upcoming market catalysts in Q1 2013.
Inui E
Nat Rev Drug Discov; 2013 Jan; 12(1):12. PubMed ID: 23274459
[No Abstract] [Full Text] [Related]
8. Market watch: upcoming market catalysts in Q2 2011.
Jeng R
Nat Rev Drug Discov; 2011 Apr; 10(4):248. PubMed ID: 21455226
[No Abstract] [Full Text] [Related]
9. Market watch: upcoming market catalysts in Q1 of 2010.
Rosenthal J
Nat Rev Drug Discov; 2010 Jan; 9(1):11. PubMed ID: 20043022
[No Abstract] [Full Text] [Related]
10. Market watch: Upcoming market catalysts in Q4 2013.
Fong S
Nat Rev Drug Discov; 2013 Oct; 12(10):731. PubMed ID: 24080689
[No Abstract] [Full Text] [Related]
11. How to improve the clinical development paradigm and its division into phases I, II and III.
Bamberger M; Moore N; Lechat P;
Therapie; 2011; 66(4):331-4, 327-30. PubMed ID: 21851796
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive therapies.
Smith RE; Ashiya M
Nat Rev Drug Discov; 2007 Aug; 6(8):597-8. PubMed ID: 17821828
[No Abstract] [Full Text] [Related]
13. Biotech's next big blowup?
Stires D
Fortune; 2002 Mar; 145(6):154. PubMed ID: 11913033
[No Abstract] [Full Text] [Related]
14. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
Binzak BA
Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
[No Abstract] [Full Text] [Related]
15. The transition from phase II to phase III studies.
Berthold DR; Gulamhusein A; Jackson JI; Tannock IF
J Clin Oncol; 2009 Mar; 27(7):1150-1. PubMed ID: 19171698
[No Abstract] [Full Text] [Related]
16. Deal watch: Novartis acquires marketing rights for novel broad-spectrum antibiotic.
Nat Rev Drug Discov; 2009 Dec; 8(12):922. PubMed ID: 19949393
[No Abstract] [Full Text] [Related]
17. Fix the antibiotics pipeline.
Cooper MA; Shlaes D
Nature; 2011 Apr; 472(7341):32. PubMed ID: 21475175
[No Abstract] [Full Text] [Related]
18. Antivirals--an increasingly healthy investment.
McCarthy B
Nat Biotechnol; 2007 Dec; 25(12):1390-3. PubMed ID: 18066033
[No Abstract] [Full Text] [Related]
19. Standardization, more funds on horizon for clinical trials.
McNeil C
J Natl Cancer Inst; 2005 Apr; 97(8):555-7. PubMed ID: 15840874
[No Abstract] [Full Text] [Related]
20. The future of drug development: advancing clinical trial design.
Orloff J; Douglas F; Pinheiro J; Levinson S; Branson M; Chaturvedi P; Ette E; Gallo P; Hirsch G; Mehta C; Patel N; Sabir S; Springs S; Stanski D; Evers MR; Fleming E; Singh N; Tramontin T; Golub H
Nat Rev Drug Discov; 2009 Dec; 8(12):949-57. PubMed ID: 19816458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
